Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call, +32

Blood

Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression

Asish K. Ghosh, Charla Secreto, Traci R. Knox, +3

Blood

Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis

Priyabrata Mukherjee, Resham Bhattacharya, Nancy D. Bone, +9

Journal of Nanobiotechnology

Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Tim G. Call, Clive S. Zent, +11

Journal of Clinical Oncology

Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells

Asish K. Ghosh, Tait D. Shanafelt, Amelia Cimmino, +12

Blood

Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG

Asish K. Ghosh, Neil E. Kay, Charla Secreto, +1

Clinical Cancer Research

The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy

Asish K. Ghosh, Charla Secreto, Justin C. Boysen, +4

Blood

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Clive S. Zent, Charla Secreto, Betsy LaPlant, +6

Leukemia Research

Hematological MalignancyLymphoid NeoplasiaComplement Dependent CytotoxicityMedicineImmunology +6

Bi‐directional activation between mesenchymal stem cells and CLL B‐cells: implication for CLL disease progression

Wei Ding, Grzegorz S. Nowakowski, Traci R. Knox, +13

British Journal of Haematology

Cell TherapyAdult Stem CellImmunologyCll B‐cellsCell Death +14

Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximab

Clive S. Zent, Timothy G. Call, Tait D. Shanafelt, +7

Cancer